Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations

Chemotherapy

Volumn 56, Issue 1, 2010, Pages 26-31

  Goudah, A ^a,b   Hasabelnaby, S ^c  

^a Cairo University   (Egypt)

^b BAYLOR UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Bioavailability; Calves; High performance liquid chromatography; Moxifloxacin; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN; MOXIFLOXACIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALF (MAMMAL); CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; CATTLE; HALF-LIFE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; QUINOLINES;

EID: 77449104816     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000290172     Document Type: Article

References (25)

1. Balfour JA, Wiseman LR: Moxifloxacin. Drugs 1999; 57: 363-373.
2. Lemoine T, Breilh D, Ducint D, Dubrez J, Jougon J, Velly JF, Saux MC: Determination of moxifloxacin (BAY 12-8039) in plasma and lung tissue by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge. J Chromatogr B 2000; 742: 247-254.
3. Kalteis T, Beckmann J, Schröder HJ, Schaumburger J, Linde HJ, Lerch K, Lehn N: Treatment of implant-associated infections with moxifloxacin: an animal study. Int J Antimicrob Agents 2006; 27: 444-448.
4. Spreng M, Deleforge J, Thomas E, Boisrame B, Drugeon H: Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates. J Vet Pharmacol Ther 1995; 18: 284-289.
5. Cester C, Schneider M, Toutain PL: Comparative kinetics of two orally administered fluoroquinolones in dog: enrofloxacin versus marbofloxacin. Rev Med Vet 1996; 147: 703-716.
6. Dalhoff A, Petersen U, Endermann R: In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410-425.
7. Brown SA: Fluoroquinolones in animal health. J Vet Pharmacol Ther 1996; 19: 1-14.
8. Gardner SY, Davis JL, Jones SL, Lafevers DH, Hoskins MS, McArver EM, Papich MG: Moxifloxacin pharmacokinetics in horses and disposition into phagocytes after oral dosing. J Vet Pharmacol Ther 2004; 27: 57-60.
9. Fernandez-Varon E, Bovaira MJ, Espuny A, Escudero E, Vancraeynest D, Carceles CM: Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration. J Vet Pharmacol Ther 2005; 27: 57-60.
10. Carceles CM, Serrano JM, Marin P, Escudero E, Fernandez-Varon E: Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. J Vet Med A 2006; 53: 300-304.
11. Fernandez-Varon E, Villamayor L, Escudero E, Espuny A, Carceles CM: Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats. Vet J 2006; 172: 302-307.
12. Carceles CM, Villamayor L, Escudero E, Marin P, Fernandez-Varon E: Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats. Vet J 2007; 173: 452-455.
13. Goudah A: Disposition kinetics of moxifloxacin in lactating ewes. Vet J 2008; 178: 282-287.
14. Stass H, Dalhoff A, Kubitza D, Schuhly U: Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-2065.
15. Ackermann MR, Brogden K: Response of the ruminant respiratory tract to Mannheimia (Pasteurella) haemolytica. Microbes Infect 2000; 2: 1079-1088.
16. Benet LZ, Hoener BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-121.
17. Siefert HM, Kohlsdorfer C, Steinke W, Witt A: Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. J Antimicrob Chemother 1999; 43(suppl B):61-67.
18. Craig AW, Suh B: Protein binding and the antibacterial effects. Method for the determination of protein binding; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 3. Baltimore, Williams & Wilkins, 1991, pp 367-402.
19. Yamaoka K, Nakagawa T, Uno T: Statistical moment in pharmacokinetics. J Pharmacokinet Biopharm 1978; 6: 547-558.
20. Gibaldi M, Perrier D: Noncompartmental analysis based on statistical moment theory. Pharmacokinetics, ed 2. New York, Marcel Dekker, 1982, pp 409-417.
21. Siefert HM, Domdey-Bette A, Henninger F, Hucke F, Kohlsdorfer C, Steinke W, Stass HH: Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 1999; 43(suppl B):69-76.
22. Nix DE, Goodwin DD, Peloquin CA, Rotella DL, Schentag JJ: Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother 1991; 35: 1953-1959.
23. Toutain PL, Del Castillo JRE, Bousquet- Melou A: The pharmacokinetic- pharmacodynamic approach to a rational dosage regimen for antibiotics. Res Vet Sci 2002; 73: 105-114.
24. Lode H, Borner K, Koeppe P: Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998; 27: 33-39.
25. Toutain PL, Lees P: Integration and modeling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. J Vet Pharmacol Ther 2004; 27: 467-477.